The European Society for Medical Oncology’s (ESMO) 18th World Congress on Gastrointestinal Cancer (WCGI) was held in Barcelona from 28th June–2nd July 2016. Presentations covered gastrointestinal (GI) cancers of every aetiology and site within the GI tract, as well as the major aspects of cancer management from screening to novel therapeutic options. Tyrosine kinase inhibitors (TKIs), with their ability to block key mechanisms required for tumour growth, featured heavily in this year’s presentations at WCGI. Data on the oral TKI regorafenib featured prominently in both poster discussion tours and oral presentations, emphasising the continuing interest in the evolution of this therapy within the clinical arsenal of physicians tackling GI cancers.
Please view the full content in the pdf above.